215. Tetralogy of Fallot Clinical trials / Disease details
Clinical trials : 18 / Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05186415 (ClinicalTrials.gov) | August 23, 2022 | 20/12/2021 | Contrast Enhanced Three Dimensional Echocardiographic Quantification of Right Ventricular Volumes in Repaired Congenital Heart Disease | Contrast Enhanced Three Dimensional Echocardiographic Quantification of Right Ventricular Volumes in Repaired Congenital Heart Disease | Tetralogy of Fallot;Pulmonary Insufficiency | Drug: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] | Nemours Children's Health System | Thomas Jefferson University | Recruiting | 11 Years | N/A | All | 60 | Phase 1/Phase 2 | United States |